グルカゴン様ペプチド1（GLP-1）アナログの世界市場-2024～2031年

概要

グルカゴン様ペプチド1（GLP-1）アナログの世界市場は2023年に512億米ドルに達し、2031年には1,904億8,000万米ドルに達すると予測され、予測期間2024～2031年のCAGRは17.9%で成長する見込みです。

グルカゴン様ペプチド-1（GLP-1）類似物質は、一般にGLP-1受容体作動薬またはインクレチン模倣薬として知られ、天然に存在するホルモンGLP-1の作用を複製する医薬品のカテゴリーです。このホルモンは食物摂取後に腸から分泌され、グルコースの調節に不可欠です。インスリンの分泌を促進し、グルカゴンの分泌を抑制し、満腹感を促進します。これらの薬は主に2型糖尿病や肥満の治療に利用され、効果的に血糖値を下げ、食欲とカロリー摂取を抑えることで体重減少を助ける。これらの要因が、世界のグルカゴン様ペプチド1（GLP-1）アナログ市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

肥満と2型糖尿病の有病率の増加

肥満と2型糖尿病の有病率の増加は、世界のグルカゴン様ペプチド1（GLP-1）アナログ市場の成長を大きく牽引しており、市場予測期間中も牽引していくと予想されます。

肥満は、健康に悪影響を及ぼす過剰な脂肪の蓄積を特徴とする慢性かつ多面的な疾患です。肥満は、2型糖尿病や心臓病の発症リスクの上昇と関連しており、骨の健康や生殖機能にも影響を及ぼす可能性があります。さらに、肥満は特定のがんの可能性を高めます。また、睡眠や運動機能などにも影響を及ぼし、生活の質にも大きな影響を与えます。

2型糖尿病と肥満の増加率は、公衆衛生上の大きな課題となっています。両疾患は、心血管疾患、高血圧、メタボリックシンドロームなどの深刻な健康合併症と関連しています。食生活の乱れや運動量の減少など、ライフスタイルの変化がこれらの疾患の罹患率の上昇につながるため、効果的な治療法に対する需要が高まっています。

世界保健機関（WHO）によると、肥満は1975年以来ほぼ3倍に増加しており、グルカゴン様ペプチド1（GLP-1）アナログのような効果的な管理戦略の緊急の必要性が強調されています。2022年には、世界の8人に1人が肥満と共存しています。成人の肥満の有病率は1990年以来2倍以上に増加し、思春期の肥満は4倍に増加しています。同年、18歳以上の成人は約25億人が太りすぎと分類され、そのうち8億9,000万人が肥満とともに暮らしていました。18歳以上の成人のうち、43％が太りすぎ、16％が肥満とされました。さらに、5歳以下の幼児の3,700万人が過体重であり、2022年には5歳から19歳の幼児と青少年の3億9,000万人以上が過体重で、うち1億6,000万人が肥満と共存しています。

さらに、パートナーシップや提携などの主要企業の戦略、臨床検査の増加や肯定的な結果は、これらのグルカゴン様ペプチド1（GLP-1）アナログ市場の成長を促進すると考えられます。例えば、2023年11月、アストラゼネカは、特に肥満とそれに関連する併存疾患の治療に焦点を当てた、心代謝性疾患市場への戦略的アプローチを発表しました。この戦略では、ECC5004として知られる最近買収したEccogeneのGLP-1受容体作動薬治療と、同社の既存の循環代謝治療、特にナトリウム-グルコース共輸送体-2（SGLT2）阻害剤Farxiga（ダパグリフロジン）を組み合わせる。

また、2024年8月、Eli Lilly and Companyは、SURMOUNT-1検査の良好なトップライン結果を発表しました。SURMOUNT-1検査は、糖尿病予備軍で肥満または過体重の成人において、週1回投与のチルゼパチド（ゼップバウンドとモウンジャロとして販売）の長期的な体重管理と糖尿病への進展遅延の有効性と安全性を評価する3年間の検査です。これらすべての要因が、世界のグルカゴン様ペプチド1（GLP-1）アナログ市場に需要をもたらしています。

さらに、治療用途の拡大がグルカゴン様ペプチド1（GLP-1）アナログの世界市場拡大に寄与しています。

薬剤費の高騰

薬剤費の高騰はグルカゴン様ペプチド1（GLP-1）アナログの世界市場の成長を阻害します。

グルカゴン様ペプチド1（GLP-1）アナログのコストが高いことが、グルカゴン様ペプチド1（GLP-1）アナログの世界市場における大きな制約となっています。毎月の治療費が約1,000ドルに達するため、特に包括的な保険に加入していない患者の多くは、これらの薬剤が法外に高価であると感じています。このような経済的負担は、多くの保険会社が高額な薬剤をカバーすることに消極的であるため、人口の大部分にとってアクセスが制限される結果となります。

2024年4月のエール大学医療部のデータによると、バイオシミラー製造業者は、インスリンを現在の米国市場価格より97％安い価格で販売できる可能性があることが調査により明らかになりました。一方、セマグルチド（オゼンピックとウェゴビー）のようなGLP-1作動薬は、米国人の1ヵ月あたりのコストが最大1,000ドルかかりますが、1ドル以下で製造できる可能性があります。

インスリンの基本推定価格は年間61ドルから111ドルで、所得水準の異なる13カ国で98ドルから1,300ドルの差がある現在の市場価格とは対照的です。同様に、GLP-1作動薬の推定月額は0.75ドルから72.49ドルと算出されたが、米国の実際の月額は約968.52ドルです。したがって、上記の要因が世界のグルカゴン様ペプチド1（GLP-1）アナログ市場の潜在的な成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 肥満と2型糖尿病の増加
  • 抑制要因
    • 高額な医薬品
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 製品別

• オゼンピック
• トルリシティ
• ムンジャロ
• ウェゴヴィ
• リュベルスス
• サクセンダ
• ヴィクトザ
• ゼップバウンド
• その他

第7章 タイプ別

• 長時間作用型GLP-1アゴニスト
• 短時間作用型GLP-1作動薬

第8章 投与経路別

• 皮下
• 経口

第9章 用途別

• 2型糖尿病
• 肥満
• その他

第10章 用途別

• 病院薬局
• 小売薬局
• オンライン薬局

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他の欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第13章 企業プロファイル

• Eli Lilly and Company
• Novo Nordisk A/S.
• Sanofi
• AstraZeneca
• Boehringer Ingelheim, Inc.
• Glenmark Pharmaceuticals Ltd.
• Hanmi Pharm.Co., Ltd.
• Amgen Inc.
• Gmax Biopharm.
• Sciwind Biosciences Co., Ltd.

第14章 付録

Overview

The global glucagon-like peptide 1 (GLP-1) analogues market reached US$51.2 billion in 2023 and is expected to reach US$190.48 billion by 2031, growing at a CAGR of 17.9 % during the forecast period 2024-2031.

Glucagon-like peptide-1 (GLP-1) analogues, commonly known as GLP-1 receptor agonists or incretin mimetics, are a category of medications that replicate the actions of the naturally occurring hormone GLP-1. The intestines secrete this hormone after food consumption which is essential for glucose regulation. It enhances insulin secretion, inhibits glucagon release, and promotes feelings of fullness. These medications are mainly utilised to treat type 2 diabetes and obesity, as they effectively lower blood sugar levels and assist in weight loss by reducing appetite and caloric intake. These factors have driven the global glucagon-like peptide 1 (GLP-1) analogues market expansion.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Obesity and Type 2 Diabetes

The increasing prevalence of obesity and type 2 diabetes is significantly driving the growth of the global glucagon-like peptide 1 (GLP-1) analogues market and is expected to drive throughout the market forecast period.

Obesity is a chronic and multifaceted disease characterized by an accumulation of excessive fat that can negatively impact health. It is associated with a heightened risk of developing type 2 diabetes and heart disease, and it can also affect bone health and reproductive functions. Additionally, obesity increases the likelihood of certain cancers. It can significantly influence the quality of life, affecting aspects such as sleep and mobility.

The rising rates of type 2 diabetes and obesity present a major public health challenge. Both conditions are linked to serious health complications, such as cardiovascular diseases, hypertension, and metabolic syndrome. As lifestyle changes, including poor dietary habits and decreased physical activity, lead to higher rates of these conditions, the demand for effective treatment options has glucagon-like peptide 1 (GLP-1) analogues.

According to the World Health Organization (WHO), obesity has nearly tripled since 1975, emphasizing the urgent need for effective management strategies such as glucagon-like peptide 1 (GLP-1) analogues. In 2022, 1 in 8 individuals globally were living with obesity. The prevalence of adult obesity has more than doubled since 1990, while adolescent obesity has seen a fourfold increase. That year, approximately 2.5 billion adults aged 18 and older were classified as overweight, with 890 million of them living with obesity. Among adults over 18, 43% were overweight and 16% were considered obese. Additionally, 37 million children under the age of 5 were overweight, and over 390 million children and adolescents aged 5 to 19 were overweight in 2022, including 160 million who were living with obesity.

Furthermore, key players' strategies such as partnerships & collaborations and the rising number of clinical trials and positive results would drive these glucagon-like peptide 1 (GLP-1) analogues market growth. For instance, in November 2023, AstraZeneca announced its strategic approach to the cardiometabolic market, particularly focusing on treating obesity and its associated co-morbidities. This strategy involves combining the recently acquired GLP-1 receptor agonist therapy from Eccogene, known as ECC5004, with their existing cardiometabolic therapies, specifically the sodium-glucose co-transporter-2 (SGLT2) inhibitor Farxiga (dapagliflozin).

Also, in August 2024, Eli Lilly and Company announced positive topline results from the SURMOUNT-1 trial, a three-year study evaluating the effectiveness and safety of tirzepatide (marketed as Zepbound and Mounjaro) administered once weekly for long-term weight management and delaying the progression to diabetes in adults with pre-diabetes and obesity or overweight. All these factors demand the global glucagon-like peptide 1 (GLP-1) analogues market.

Moreover, the expanding therapeutic applications contribute to the global glucagon-like peptide 1 (GLP-1) analogues market expansion.

High Cost of Medications

The high cost of medications will hinder the growth of the global glucagon-like peptide 1 (GLP-1) analogues market.

The high cost of glucagon-like peptide 1 (GLP-1) analogues serves as a significant constraint in the global market for these medications. With monthly treatment expenses reaching about $1,000, many patients find these drugs prohibitively expensive, particularly those without comprehensive insurance coverage. This financial strain results in limited access for a large segment of the population, as numerous insurance providers are reluctant to cover these costly medications.

According to the Yale School of Medicine data in April 2024, research has revealed that biosimilar manufacturers could sell insulin at prices 97% lower than current U.S. market rates, while GLP-1 agonist drugs like semaglutide (Ozempic and Wegovy), which cost Americans up to $1,000 per month, could potentially be produced for less than $1.

The estimated cost-based prices for insulin ranged from $61 to $111 annually, in stark contrast to the current market prices, which vary between $98 and $1,300 across 13 countries with different income levels. Similarly, the estimated monthly prices for GLP-1 agonists were calculated to be between $0.75 and $72.49, whereas the actual monthly price in the U.S. is approximately $968.52. Thus, the above factors could be limiting the global glucagon-like peptide 1 (GLP-1) analogues market's potential growth.

Segment Analysis

The global glucagon-like peptide 1 (GLP-1) analogues market is segmented based on product, type, route of administration, application, distribution channel, and region.

Product:

The Ozempic segment is expected to dominate the global glucagon-like peptide 1 (GLP-1) analogues market share

The Ozempic segment holds a major portion of the global glucagon-like peptide 1 (GLP-1) analogues market share and is expected to continue to hold a significant portion of the global glucagon-like peptide 1 (GLP-1) analogues market share during the forecast period.

Glucagon-like peptide-1 (GLP-1) is a physiological hormone that plays a crucial role in glucose metabolism. It exerts its effects through the GLP-1 receptor (GLP-1R), which is found in various cell types, including pancreatic beta cells. Ozempic, a GLP-1 receptor agonist, selectively binds to and activates the GLP-1 receptor, mimicking the action of native GLP-1.

Ozempic is a modified form of GLP-1 with approximately 94% sequence homology to human GLP-1. Structural modifications enhance its pharmacological properties. These modifications result in a longer half-life, allowing for once-weekly dosing rather than daily administration. The alterations make Ozempic resistant to enzymatic breakdown by dipeptidyl peptidase IV (DPP-IV), which normally degrades native GLP-1 rapidly.

Furthermore, key players in the industry product launches and approvals would drive this segment's growth in the global glucagon-like peptide 1 (GLP-1) analogues market. For instance, in March 2022, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved a new 2.0 mg dose of Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) analogue, for the treatment of adults with type 2 diabetes. This approval expands the available dosing options for Ozempic, which now includes 0.5 mg, 1.0 mg, and the newly approved 2.0 mg doses.

These factors have solidified the segment's position in the global glucagon-like peptide 1 (GLP-1) analogues market.

Geographical Analysis

North America is expected to hold a significant position in the global glucagon-like peptide 1 (GLP-1) analogues market share

North America holds a substantial position in the global glucagon-like peptide 1 (GLP-1) analogues market and is expected to hold most of the market share.

The rising rates of obesity and type 2 diabetes in North America are driving the demand for effective treatment options. As more individuals are diagnosed with these conditions, the need for glucagon-like peptide 1 (GLP-1) analogues therapies continues to grow.

North America benefits from a well-established healthcare system that supports the adoption of advanced therapies. This infrastructure facilitates patient access to glucagon-like peptide 1 (GLP-1) analogues, ensuring that healthcare providers can effectively prescribe and monitor these treatments. The presence of favourable reimbursement frameworks in the U.S. encourages healthcare providers to prescribe glucagon-like peptide 1 (GLP-1) analogues.

Moreover, in this region, a major number of key players present, government initiatives & regulatory support, technological advancements, & investments and product launches & approvals that would propel this glucagon-like peptide 1 (GLP-1) analogues market growth. For instance, in November 2023, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's Zepbound (tirzepatide) injection, marking it as the first and only obesity treatment that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

Also, in May 2022, the U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide) injection, developed by Eli Lilly and Company, as a once-weekly treatment for adults with type 2 diabetes. Mounjaro acts as a dual receptor agonist, targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This medication is intended to be used in conjunction with diet and exercise to enhance glycemic control. Thus, the above factors are consolidating the region's position as a dominant force in the global glucagon-like peptide 1 (GLP-1) analogues market.

Asia Pacific is growing at the fastest pace in the global glucagon-like peptide 1 (GLP-1) analogues market

Asia Pacific holds the fastest pace in the global glucagon-like peptide 1 (GLP-1) analogues market and is expected to hold most of the market share.

The Asia-Pacific glucagon-like peptide 1 (GLP-1) analogues market is experiencing significant growth, driven by various factors that address the increasing prevalence of diabetes and obesity in the region.

The Asia-Pacific region is seeing a notable increase in cases of type 2 diabetes and obesity, primarily due to lifestyle changes, urbanization, and unhealthy dietary habits. This surge in diagnoses is fueling the demand for effective treatment options like glucagon-like peptide 1 (GLP-1) analogues. The ageing demographic in Asia-Pacific is projected to grow significantly, with individuals aged 60 and above expected to nearly double by 2050. Older adults are more susceptible to developing type 2 diabetes, which will drive the demand for GLP-1 therapies designed to manage their health effectively.

Furthermore, key players in the region product launches and approvals that would drive this glucagon-like peptide 1 (GLP-1) analogues market. For instance, in January 2024, Glenmark Pharmaceuticals Ltd. made a significant entry into the Indian pharmaceutical market by launching Lirafit, a biosimilar of the widely used anti-diabetic drug liraglutide. This marks the first time a biosimilar of liraglutide has been introduced in India, following approval from the Drug Controller General of India (DCGI).

Also, in November 2023, semaglutide, marketed under the brand name Wegovy, received regulatory approval for chronic weight management in Japan. This marks a significant milestone as it is the first GLP-1 receptor agonist approved for obesity treatment in Japan, and indeed the first such approval for chronic weight management in any Asian country.

Thus, the above factors are consolidating the region's position as the fastest-growing force in the global glucagon-like peptide 1 (GLP-1) analogues market.

Competitive Landscape

The major global players in the glucagon-like peptide 1 (GLP-1) analogues market include Eli Lilly and Company, Novo Nordisk A/S., Sanofi, AstraZeneca, Boehringer Ingelheim, Inc., Glenmark Pharmaceuticals Ltd., Hanmi Pharm.Co., Ltd., Amgen Inc., Gmax Biopharm., and Sciwind Biosciences Co., Ltd. among others.

Key Developments

• In August 2024, Metsera, a newly launched clinical-stage biopharmaceutical company, emerged with a significant $290 million in funding to develop innovative treatments for obesity and metabolic diseases, particularly focusing on GLP-1 receptor agonists.
• In June 2024, Teva Pharmaceuticals announced the launch of the first generic version of a GLP-1 receptor agonist in the United States, specifically liraglutide 1.8 mg. This marks a significant milestone in the diabetes treatment landscape as it introduces a more affordable option for patients managing type 2 diabetes.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global glucagon-like peptide 1 (GLP-1) analogues market report would provide approximately 78 tables, 76 figures, and 183 pages.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product
• 3.2. Snippet by Type
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Application
• 3.5. Snippet by Distribution Channel
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of Obesity and Type 2 Diabetes
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of Medications
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. By Product

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product
  • 6.1.2. Market Attractiveness Index, By Product
• 6.2. Ozempic*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Trulicity
• 6.4. Mounjaro
• 6.5. Wegovy
• 6.6. Rybelsus
• 6.7. Saxenda
• 6.8. Victoza
• 6.9. Zepbound
• 6.10. Others

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Long-acting GLP-1 Agonist*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Short-acting GLP-1 Agonist

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Subcutaneous*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Oral

9. By Application

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.1.2. Market Attractiveness Index, By Application
• 9.2. Type 2 Diabetes Mellitus*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Obesity
• 9.4. Others

10. By Application

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.1.2. Market Attractiveness Index, By Application
• 10.2. Hospital Pharmacies*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.8.1. U.S.
    • 11.2.8.2. Canada
    • 11.2.8.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.8.1. Germany
    • 11.3.8.2. U.K.
    • 11.3.8.3. France
    • 11.3.8.4. Spain
    • 11.3.8.5. Italy
    • 11.3.8.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.8.1. Brazil
    • 11.4.8.2. Argentina
    • 11.4.8.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.8.1. China
    • 11.5.8.2. India
    • 11.5.8.3. Japan
    • 11.5.8.4. South Korea
    • 11.5.8.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Eli Lilly and Company*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Novo Nordisk A/S.
• 13.3. Sanofi
• 13.4. AstraZeneca
• 13.5. Boehringer Ingelheim, Inc.
• 13.6. Glenmark Pharmaceuticals Ltd.
• 13.7. Hanmi Pharm.Co., Ltd.
• 13.8. Amgen Inc.
• 13.9. Gmax Biopharm.
• 13.10. Sciwind Biosciences Co., Ltd.

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us